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Abstract
Hospitalization for acute heart failure (HF) is associated with a substantial morbidity burden and with associated healthcare
costs and an increased mortality risk. However, few if any major medical innovations have been witnessed in this area in re-
cent times. Levosimendan is a ﬁrst-in-class calcium sensitizer and potassium channel opener indicated for the management of
acute HF. Experience in several clinical studies has indicated that administration of intravenous levosimendan in intermittent
cycles may reduce hospitalization and mortality rates in patients with advanced HF; however, none of those trials were de-
signed or powered to give conclusive insights into that possibility. This paper describes the rationale and protocol of LeoDOR
(levosimendan infusions for patients with advanced chronic heart failure), a randomized, double-blind, placebo-controlled, in-
ternational, multicentre trial that will explore the efﬁcacy and safety of intermittent levosimendan therapy, in addition to op-
timized standard therapy, in patients following hospitalization for acute HF. Salient features of LeoDOR include the use of two
treatment regimens, in order to evaluate the effects of different schedules and doses of levosimendan during a 12 week treat-
ment phase, and the use of a global rank primary endpoint, in which all patients are ranked across three hierarchical groups
ranging from time to death or urgent heart transplantation or implantation of a ventricular assist device to time to rehospi-
talization and, lastly, time-averaged proportional change in N-terminal pro-brain natriuretic peptide. Secondary endpoints in-
clude changes in HF symptoms and functional status at 14 weeks.
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Introduction
Heart failure (HF) is the leading cause of adult hospitalization
in the industrialized world and imposes a substantial burden
on public health. Healthcare costs for HF patients are high
and rising,1 driven by an increase in hospitalizations related
to HF.2 Over recent decades, adoption of evidence-based
therapies has reduced the event rate in patients with chronic
HF.3 However, the therapeutic approach for hospitalized pa-
tients with acute HF has remained practically unchanged,
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and outcomes for these patients are still poor4,5: hospitaliza-
tion for acute HF is associated with higher mortality, recur-
rent hospitalization, and increased resource consumption.4,6
In a European survey, 1 year mortality was 23.6% for individ-
uals hospitalized with acute HF, compared with 6.4% for out-
patients with chronic HF.4 The majority of rehospitalizations
occur early after hospital discharge: about a quarter of pa-
tients are rehospitalized within the ﬁrst month and two-
thirds within 1 year.2,7
Strategies to prevent rehospitalizations during this
vulnerable period have not been consistently successful so
far, although adherence to well-established medical
therapies at optimal doses is considered essential.5
Recently, sacubitril/valsartan,8 ivabradine,9 and cardiac
resynchronization therapy10 were found to reduce both hospi-
talizations and rehospitalizations. Intermittent or continuous
inotropic therapy has also been tested, but, despite favourable
haemodynamic and symptomatic improvement in pilot trials,11
no positive effect on hospitalizations has been observed, and,
in fact, there has been a trend towards a highermortality risk.12
Levosimendan, a calcium sensitizer and potassium channel
opener, is indicated for acute HF. The compound has an active
metabolite (OR1896) that prolongs its effects beyond the infu-
sion period.13 The theoretical advantages of levosimendan in
comparison with traditional inotropic agents include (i) a lack
of increase in intracellular calcium concentration and thus no
increase in myocardial oxygen demand; (ii) prolonged effects
via the formation of an active metabolite; (iii) beneﬁcial symp-
tomatic, neurohormonal, and haemodynamic effects (e.g. de-
crease in pulmonary capillary wedge pressure and increase in
cardiac output); (iv) no attenuation of effect in patients using
beta-blockers; and (v) beneﬁcial effects on renal function and
peripheral organ perfusion.14 Several clinical studies of the re-
petitive use of intravenous (i.v.) levosimendan have suggested
that such a strategy may beneﬁt patients with advanced HF
by reducing hospitalization and mortality.15–17 However, some
of these studies were open-label, single-centre studies, and
even the largest, double-blind trial performed to date—
LevoRep (NCT01065194)17—was limited to 120 patients.
Therefore, a larger study is needed to verify these favourable
preliminary results.18,19
In this paper, the design of the randomized, double-blind,
placebo-controlled LeoDOR (levosimendan infusions for pa-
tients with advanced chronic heart failure) trial is presented.
This study will assess the efﬁcacy and safety of intermittent
levosimendan therapy started during the vulnerable phase
following a hospitalization for acute HF. The overarching hy-
pothesis is that, compared with placebo, repetitive adminis-
tration of levosimendan during the post-acute phase will be
associated with greater clinical stability over a follow-up pe-
riod of 14 weeks.
Study design
The LeoDOR (Figure 1) is a multicentre, randomized, double-
blind, placebo-controlled, three-arm trial designed to evalu-
ate the efﬁcacy and safety of intermittent levosimendan
therapy, administered in addition to standard therapy for a
period of 12 weeks either as a 6 h continuous infusion at a
rate of 0.2 μg/kg/min every 2 weeks or as a 24 h continuous
infusion at a rate of 0.1 μg/kg/min every 3 weeks. The pri-
mary endpoint will be evaluated after 14 weeks. Another
follow-up visit to obtain information on safety events is
scheduled after 6 months. The study intends to include 264
patients in 28 centres in nine European countries.
Appraisal of levosimendan efﬁcacy in LeoDOR is based on a
hierarchical composite outcome. The primary efﬁcacy assess-
ment will be made using a global rank endpoint in which all
participants are ranked across three hierarchical groups:
(i) time to death or urgent heart transplantation or
Figure 1 Schematic diagram of study design for LeoDOR trial. IP, investigational product.
Rationale and design of the LeoDOR trial 175
ESC Heart Failure 2019; 6: 174–181
DOI: 10.1002/ehf2.12366
implantation of a ventricular assist device (VAD); (ii) time to
non-fatal HF requiring i.v. vasoactive therapy; and (iii) time-
averaged proportional change in N-terminal pro-brain natri-
uretic peptide (NT-proBNP) from baseline to Week 14 with
(i) as the most important event. Secondary efﬁcacy endpoints
include individual components of the primary endpoint at
short-term (14 weeks) and intermediate-term (26 weeks)
follow-up, as well as changes in functional status.
The LeoDOR Executive Committee (Appendix) designed the
trial and wrote the study protocol. The protocol was ap-
proved by the Ethics Review Committee/Institutional Review
Board afﬁliated to each centre, and the study will be
conducted in accordance with Good Clinical Practice and
the 2002 Declaration of Helsinki. All participants will provide
written informed consent prior to any study-related investi-
gations. The trial has been registered at https://clinicaltrials.
gov, NCT03437226.
Study population and inclusion/exclusion criteria
The study population will include male and female patients
aged ≥18 years hospitalized for an acute HF event requiring i.
v. diuretics, i.v. vasodilators, i.v. inotropic therapy, or any com-
bination of those interventions. Patients must have had a diag-
nosis of chronic HF for ≥6 months prior to screening and must
have been treated with individually optimized long-term thera-
pies for ≥1 month preceding the index hospitalization. Further
inclusion criteria are left ventricular ejection fraction ≤30%
assessed during index hospitalization, at least one previous
hospitalization or visit to an outpatient clinic for acute decom-
pensated HFwithin the 12months before the index hospitaliza-
tion and either NT-proBNP levels (as measured by the local
laboratory) after recompensation of ≥2500 ng/L (BNP
≥900 ng/L) or persistent New York Heart Association functional
class III or IV at study entry. Patients are considered
recompensated and ready for discharge when haemodynami-
cally stable, euvolemic, established on evidence-based oral
medication, and with stable renal function for at least 24 h.20
Patients with severe obstruction of the ventricular outﬂow
tract, severely impaired ventricular ﬁlling such as restrictive
cardiomyopathy, predominantly right-sided HF and/or severe
tricuspid regurgitation, cardiac surgery, coronary angioplasty,
or acute coronary syndromes within 30 days of initiation of
study drug are not eligible. Further exclusion criteria include
patients scheduled for cardiac surgery or angioplasty within
the next 3 months; history of torsades de pointes; stroke or
transient ischaemic attack within 3 months of initiation of
study drug; systolic blood pressure ≤90 mmHg or heart rate
≥120 beats/min at baseline; serum potassium <3.5 mmol/L
before initiation of study drug; estimated glomerular ﬁltration
rate <30 mL/min/1.73 m2; haemoglobin <10 g/dL; signiﬁcant
hepatic impairment; hypersensitivity to levosimendan; other
serious diseases that considerably limit life expectancy; preg-
nancy or lactation; and administration of levosimendan within
14 days of initiation of study drug (Table 1).
Table 1 LeoDOR inclusion and selected exclusion criteria
Inclusion criteria
Male and female patients aged >18 years
HF diagnosed at least 6 months before screening and treated with individually optimized long-term oral and device treatment for the
last month, unless not tolerated
LVEF ≤30% as assessed using echocardiography, radionuclide ventriculography, or contrast angiography during the index hospitalization
Currently hospitalized for decompensated HF requiring i.v. diuretics or i.v. vasodilators or i.v. inotropic therapy
Previous hospitalization or visit to an outpatient clinic requiring i.v. diuretics, i.v. vasodilators, or i.v. inotropic therapy for acute
decompensated HF within 12 months prior to index hospitalization
NT-proBNP level (as measured by the local laboratory) after compensation of ≥2500 ng/L and/or NYHA class III or IV at study entry. A
compensated status is reached when the patient is haemodynamically stable, euvolemic, established on evidence-based oral
medication, and with stable renal function for at least 24 h
Exclusion criteria
Severe obstruction of ventricular outﬂow tracts, such as haemodynamically signiﬁcant uncorrected primary valve disease or
hypertrophic cardiomyopathy or impaired ventricular ﬁlling, such as restrictive cardiomyopathy
Predominantly right-sided heart failure and/or severe tricuspid regurgitation
Cardiac surgery or coronary angioplasty within 30 days prior to study drug initiation
Acute coronary syndromes within 30 days prior to study drug initiation
Patients scheduled for cardiac surgery or angioplasty in the next 3 months
History of torsades de pointes
Systolic blood pressure <90 mmHg at baseline
Heart rate ≥120 beats/min at baseline
Serum potassium <3.5 mmol/L before study drug initiation
eGFR ≤30 mL/min/1.73 m2
Administration of levosimendan within 14 days prior to study drug initiation (ﬁrst study drug application to be postponed for at least
14 days after the end of this premedication)
Hypersensitivity to levosimendan
Other serious diseases that considerably limit life expectancy (e.g. end-stage cancer, end-stage renal disease, and end-stage lung disease)
eGFR, estimated glomerular ﬁltration rate; HF, heart failure; i.v., intravenous; LVEF, left ventricular ejection fraction; NT-proBNP, N-termi-
nal pro-brain natriuretic peptide; NYHA, New York Heart Association.
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Patients will be randomized after recompensation from
the index episode of acute HF. Randomization can take place
either at the end of the hospital stay or within 14 days after
discharge for the index hospitalization.
Study treatment
Candidates for the study will be screened during hospitaliza-
tion for acute decompensated HF. During the ﬁrst treatment
visit, eligibility for the trial will be conﬁrmed, the patient will
be randomized, and the ﬁrst infusion of the study drug will be
administered. The ﬁrst treatment visit should preferentially
be scheduled during the index hospitalization or, at the latest,
within 14 days after discharge from hospital. If the baseline
visit takes place during the index hospitalization, the patient’s
condition should be stabilized so as to facilitate administra-
tion of the study drug on the last day of the index
hospitalization.
Levosimendan or matching placebo will be administered as
an i.v. infusion. For the 6 h infusion group, the study drug will
be administered at a continuous infusion rate of 0.2 μg/kg/min
for 6 h. The scheduled study drug administrations will take
place on Day 0, Day 14 (±2 days), Day 28 (±2 days), Day 42
(±2 days), Day 56 (±2 days), Day 70 (±2 days), and Day 84
(±2 days). For the 24 h infusion group, the study drug will be ad-
ministered at a continuous infusion rate of 0.1 μg/kg/min for
24 h. The scheduled study drug administrations will take place
on Day 0, Day 21 (±3 days), Day 42 (±3 days), Day 63 (±3 days),
and Day 84 (±3 days) (Figure 1).
At Day 84, the study medication will be stopped for all pa-
tients; a follow-up visit will be arranged for 14 days (±2 days)
after cessation of treatment. A second follow-up visit will be
arranged at 180 days (±14 days) after initiation of study
medication.
Study assessments
Components of the primary endpoint, which comprises
death, urgent heart transplantation or VAD implantation, as
well as non-fatal acute HF events, will be reported from re-
ceipt of completed patient informed consent forms until
Week 26. All reported events will be adjudicated by the End-
point Adjudication Committee (Appendix).
A ‘non-fatal acute HF event’ is deﬁned as presentation of
the patient for an urgent, unscheduled visit at a clinic, ofﬁce,
emergency department, or hospital with a primary diagnosis
of HF, i.e. where the patient exhibits new or worsening symp-
toms of HF on presentation, has objective evidence of new or
worsening HF, and receives i.v. vasoactive therapy, deﬁned
according to Hicks et al.21 as i.v. diuretics, i.v. vasodilators,
i.v. inotropes, or any combination of those interventions.
N-terminal pro-brain natriuretic peptide will be assessed at
baseline and at Weeks 6, 12, and 14. Biomaterials will be
shipped to and stored and analysed at the Interdisciplinary
Bank of Biomaterials and Data, University of Würzburg.
Symptoms and functional status will be assessed at base-
line and at Week 14 using the following instruments: (i) the
Kansas City Cardiomyopathy Questionnaire, a self-
administered, 23-item questionnaire that quantiﬁes physical
limitation and quality of life in patients with HF.22 Changes
in clinical summary score will be used for analyses; (ii) the
6 min walk test conducted according to the guidelines for
the six-minute walk test published by the American Thoracic
Society23; and (iii) New York Heart Association HF classiﬁca-
tion recorded by the investigator.
The seven-item patient’s global assessment (PGA) is sched-
uled to take place at Week 14 after beginning administration
of the study drug and will be conducted before any other as-
sessment, interview, or study drug administration, so that the
answers will not be inﬂuenced by the study procedures.24 For
patients hospitalized for any reason by the planned date of
the PGA, every effort will be made to conduct it. If the PGA
cannot be performed in a hospital, the patient will be catego-
rized as ‘hospitalized’ and ranked under the category ‘much
worse’. Patients who die on or before the planned date of
PGA will be categorized as ‘died’ and ranked under the cate-
gory ‘hospitalized’.
Cost-effectiveness will be assessed using the ﬁve-level
version of the EuroQol EQ-5D questionnaire, which will be
completed by the patient at baseline and Week 14.25
Endpoint selection
Primary endpoint
The primary efﬁcacy objective of the study is to compare the
effects of pulsed application of levosimendan versus placebo
in patients with advanced chronic heart failure during a vul-
nerable period of 14 weeks following a recent hospitalisation
on a global rank endpoint, in which all participants are ranked
across three hierarchical groups (in ascending order):
• time to death or urgent heart transplantation or implanta-
tion of a VAD;
• time to a non-fatal HF event requiring i.v. vasoactive
therapy (i.v. diuretics, i.v. vasodilators, or i.v. inotropes); and
• time-averaged proportional change in NT-proBNP from
baseline to 14 weeks.
Secondary endpoints
The secondary efﬁcacy objectives are to determine the ef-
fects of pulsed application of levosimendan on the individual
components of the primary endpoint at 14 and 26 weeks
(time-averaged proportional change in NT-proBNP will be de-
termined from baseline to 14 weeks only), plus changes in
Rationale and design of the LeoDOR trial 177
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symptoms and functional status at 14 weeks and the cumula-
tive number of acute HF events and cumulative days alive
and out of hospital at 14 and 26 weeks.
Additional study objectives are to determine the effects of
pulsed application of levosimendan on changes in background
medication and biomarkers, as well as cost-effectiveness.
Statistical considerations and randomization
The statistical hypothesis is that, compared with placebo,
levosimendan in patients with advanced HF will be associated
with greater clinical stability as assessed using a global rank
endpoint, which is a composite of (i) time to death or urgent
heart transplantation or VAD implantation, (ii) time to a non-
fatal HF event requiring i.v. vasoactive therapy, and (iii) time-
averaged proportional change in NT-proBNP from baseline to
14 weeks. Patients will be ranked so that those who meet
component (i) will get the lowest rank starting with Rank 1
for the patient with the earliest endpoint. Thereafter, pa-
tients meeting component (ii) will be ranked similarly, where
the patient with the earliest endpoint is ranked the number
of deaths plus 1. Finally, patients who do not meet compo-
nents (i) or (ii) will be ranked so that those who respond best
(i.e. who have the largest decline in NT-proBNP) will get the
highest rank (equal to sample size).
Statistical assumptions of rates of death and acute HF
events in the placebo group (10% and 30%, respectively)
are based on data from Gheorghiade et al.,26 Cowie et al.,27
and OPTIME-CHF.28 Effect-size assumptions for repetitive
levosimendan treatment (20% relative risk reduction for
death and acute HF) are derived from experience in the
LevoRep,17 LionHeart,29 and LAICA (NCT00988806; unpub-
lished data, from personal communication with Martín Jesús
García-Gonzáles) trials.
Assuming a total of 264 patients (6 h infusion group:
levosimendan, n = 88; placebo, n = 44; 24 h infusion group:
levosimendan, n = 88; placebo, n = 44), LeoDOR has ≈90%
simulated power to detect a difference between the pooled
levosimendan and placebo groups at a two-sided signiﬁcance
level of 5% using the Wilcoxon–Mann–Whitney test. Using
the same simulation model, the individual components of
the global rank endpoint (death, acute HF, and ΔNT-proBNP)
have ≈10%, ≈20%, and ≈99% power, respectively, to detect a
difference between groups.
The intention-to-treat data set including all randomized
patients will be used for the primary evaluation. Sensitivity
analyses using the per-protocol data set will be considered
and will be described in the statistical analysis plan should a
meaningful number of patients exhibit major protocol viola-
tions. All patients who receive any study treatment will be in-
cluded in the safety evaluation.
Patients will be randomized to receive either levosimendan
or matching placebo in a ratio of 2:1. Clinical effect is assumed
to be similar between the two infusion schedules, and the sta-
tistical hypothesis will compare the pooled levosimendan con-
tingent with the pooled placebo group. Of note, the infusion
schedule (6 or 24 h) is not part of the randomization or strat-
iﬁcation scheme; the infusion group will be selected based on
centre preference or convenience for the patient. Randomiza-
tion will be balanced at each centre using randomly
permutated blocks speciﬁc for each centre and infusion group.
Study schedule
The ﬁrst patients will be enrolled in LeoDOR in February
2018. The recruitment period will last for 16 months until
June 2019. Study completion is anticipated in February 2020.
Discussion
The aim of the LeoDOR trial is to investigate efﬁcacy and
safety of intermittent levosimendan therapy during the vul-
nerable phase after a recent hospitalization for acute HF in
advanced HFrEF patients.
Hospitalization for the management of acute decompensa-
tion is a sentinel event in the trajectory of HF and one that
has important prognostic implications.27 Readmission and
mortality rates are particularly high during the 3 month period
after discharge. Rehospitalizations during this early discharge
period, which is also known as the ‘vulnerable phase’, account
for a disproportionate amount of the extensive overall costs of
HF care. Although up to 75% of early readmissions may be pre-
ventable,30 effective measures to prevent rehospitalizations
during this vulnerable period remain ill deﬁned.
Recent meta-analyses suggest that repetitive levosimendan
may reduce hospitalization and mortality in patients with ad-
vancedHF.15,16 Individual studies, including the LevoREP trial,17
were, however, underpowered to provide deﬁnite conclusions
regarding these endpoints. Accordingly, the LeoDOR trial is
powered to compare the effects of repetitive administration
of levosimendan vs. placebo during the vulnerable post-
discharge period following hospital admission for acute HF
using a hierarchical composite endpoint including death and
rehospitalization. Efﬁcacy will be tested 14 weeks after the ﬁrst
infusion; a safety endpoint including death and hospitalization
is scheduled for 12 weeks after the ﬁrst infusion.
Rationale for study design and endpoint selection
Outpatient therapy and management is highly desirable for
patients with advanced HF and compromised quality of life,
which is often related to repeat HF-related hospitalizations.
In this context, repetitive infusions of levosimendan in an am-
bulatory setting appear promising. Such a strategy is safe, as
evidenced by the LevoRep17 and LionHEART.29 The LeoDOR
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trial will follow this concept. A second active-treatment study
arm with a 24 h continuous infusion of levosimendan is in-
cluded to meet the infrastructural and economic require-
ments of countries and centres that currently do not
support ambulatory therapy in advanced HF. To achieve com-
parable cumulative drug doses in both treatment arms, the
dosage per hour (0.2 vs. 0.1 μg/kg/min) and the number of
infusions (seven vs. ﬁve repetitions) will be higher in the
6 h arm compared with the 24 h arm. Patients will be allo-
cated to levosimendan or placebo in a ratio of 2:1.
Endpoint selection for high-risk HF populations is critical and
is often the subject of debate. The main clinical targets are to
relieve symptoms, to reduce the number and length of hospi-
talizations, and, ultimately, to reduce mortality. Symptomatic
improvement has turned out to be a problematic endpoint in
HF trials as confounding factors may inﬂuence its reliable mea-
surement. A composite endpoint comprising mortality and
rehospitalizations would potentially have wide acceptance.31
However, this approach might create substantial problems in
interpreting trial results as both components of the composite
would be treated equally, despite the fact that clinicians and
patients may attach different values to the speciﬁc compo-
nents. Furthermore, thresholds for hospitalization vary sub-
stantially between institutions and countries, and
hospitalizations tend to occur more frequently than mortality
events and therefore have a greater effect on the endpoint.
This applies particularly when a ‘time-to-event’method is used,
where patients are followed up until the ﬁrst event of the com-
posite endpoint. Furthermore, the components of the compos-
ite may ‘move’ in different directions, which can further
complicate coherent interpretation of the study results.32 Fi-
nally, restricting the combined endpoint to mortality and hospi-
talization requires a substantially large sample size and/or a
considerably long follow-up period.
An approach that assigns proper weight to different out-
comes and also enables every patient to contribute to the
endpoint would optimize the feasibility of a study, without
compromising the clinical impact that may be derived from
trial results.32
A study in advanced HF with a primary endpoint combining
death, rehospitalization, and positive neurohormonal re-
sponse has been published recently.33 Each patient was
assigned a global rank score based on their outcomes during
follow-up. The components were analysed in a hierarchical
manner so that deaths were the most important events,
followed by rehospitalizations and, ﬁnally, effect on NT-
proBNP. No statistically resilient treatment effect was dem-
onstrated in that study, but the credibility of the outcome-
ranking methodology was demonstrated.
The LeoDOR will apply a similar endpoint methodology for
the assessment of repetitive cycles of levosimendan in theman-
agement of patients who have experienced a recent hospitaliza-
tion for acutely decompensated HF. Adding changes in NT-
proBNP over time as an additional component also allows a
more comprehensive interpretation of the effects of the study
drug on the complex trajectory after discharge. As shown re-
cently, follow-up BNP level and per cent change in BNP within
3months after discharge were predictors of long-termmortality
but were also superior to BNP levels on hospital admission.34
In summary, the LeoDOR trial will test efﬁcacy and safety
of intermittent levosimendan therapy in patients with ‘very’
advanced but not acute HF with the highest short-term and
long-term mortality and rehospitalization rates.3,19,20
Perspective
The concept of pulsed administration of levosimendan for pa-
tients with advanced HF during the vulnerable phase after a re-
cent hospitalization for acute HF, as will be tested in the
LeoDOR trial, potentially represents an important contribution
to the therapeutic armamentarium for such patients. In partic-
ular, the study is conﬁgured to examine evidence of efﬁcacy of
an intensiﬁed therapy using clinically relevant endpoints for se-
verely ill patients managed on an outpatient basis.
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